Dear customers, please be informed that our shopping cart will be unavailable between August 21 and September 1, 2014, as we will be making some changes to serve you better. To minimise any possible delivery disruption, we encourage you to make your purchases before August 21. We appreciate your understanding and apologise for any inconvenience.

Wiley
Wiley.com
Print this page Share
E-book

Biotech Funding Trends: Insights from Entrepreneurs and Investors

ISBN: 978-3-527-62274-0
300 pages
December 2008, Wiley-Blackwell
Biotech Funding Trends: Insights from Entrepreneurs and Investors (3527622748) cover image
Based on interviews with successful biotech entrepreneurs and high-level investors as well as case studies, this title provides a comprehensive overview of current trends in biotech funding. In particular, it illustrates the tensions between both sides based on their different backgrounds and expectations. The book outlines the various funding opportunities for the biotech industry and identifies ways for both sides to overcome their existing prejudices in order to successfully thrive in a competitive environment.
A must-have for biotech entrepreneurs and investors, as well as invaluable supplementary reading for students aspiring to a career in the industry.
See More
INTRODUCTION
Development of the Private Equity and Venture Capital Market
Development of the Biotech Industry
METHODOLOGY
Formulating the Research Goal
Conducting the Study
Evaluating the Results
DATA ANALYSIS AND INTERPRETATION OF RESULTS
Description of Interview Partners
Major Characteristics of an Entrepreneur
Major Characteristics of a Venture Capitalist
The Most Important Partnering Criteria
Financing Models
Biotech Research Areas
Alliances and Funding in the Early Stage
Alliances and Funding in the Late Stage
Exit Routes
Primary Causes of Failure
Best-practice Countries for Funding Biotech Start-ups
Striking Differences between the US and European Venture Capital Markets
BIOTECH CASE STUDIES
AUSTRIANOVA Biomanufacturing AG
AVIR Green Hills Biotechnology AG
EUCODIS GmbH
Intercell AG
onepharm Research & Development GmbH
SUMMARY AND CONCLUSIONS
The Challenge: When Science Meets Business
Checklists
Final Observations
OUTLOOK AND RECOMMENDATIONS
EPILOGUE
REFERENCES
APPENDICES
See More
Alexandra Carina Gruber, born in 1971 in Vienna, Austria, has been working in the pharmaceutical industry for the past 12 years, where she has held various marketing and business development positions and developed a profound expertise in the marketing and licensing of biotech and generic products. She is currently Director of Business Development & Marketing at BIOCRATES Life Sciences in Innsbruck Austria.
See More
  • Provides a comprehensive overview of current trends in biotech funding

  • Based on interviews with dedicated biotech entrepreneurs and high-level investors as well as case studies

  • Illustrates the tensions between both sides based on their different backgrounds and expectations

  • Identifies ways for both sides to overcome their existing prejudices in order to successfully thrive in a competitive environment

  • Outlines the various funding opportunities for the biotech industry in Europe

See More
"Ein interessantes Buch über die europäische Biotechnologie-Industrie und ihre Finanzierungs-Strategien-, respektive -Möglichkeiten, liegt nun vor, geschrieben von der Wiener Pharmazeutin Mag. Pharm. Dr. A. C. Gruber, basierend auf ihrer Masterarbeit für den Executive MBA an der Wirtschaftsuniversität Wien und an der University of Minnesota und weiteren Post-doc-Studien in Krems (Donauuniversität) und an der University of British Columbia in Vancouver, Kanada. Aus der Zusammenfassung und persönlichen Bewertungen vieler Interviews mit Wissenschaftlern, erfahrenen Unternehmern, Risikokapital-Anlegern, Investoren und hochrangigen Experten entstand diese Übersicht über neue Trends betreffend Geldanlagen, Finanzierungen mit tieferen Einblicken in den europäischen Biotechnologie-Markt. Das Buch gliedert sich in eine Kurzzusammenfassung, gefolgt von 6 Kapiteln und einem Epilog, einer Literaturliste, 4 Anhängen und einem Sachindex. Nach der Einleitung über privates Beteiligungskapital und dem Risikokapital-Markt (Kapitel 1) und der Methodologie (Kapitel 2, welches Finanzierungsmöglichkeiten behandelt) folgen "Data Analysis and Interpretation of Results" (Kapitel 3), "Biotech Case Studies" (Kapitel 4), "Summary and Conclusions" (Kapitel 5) und das Kapitel 6 über "Outlook and Recommendations". Die Autorin versteht es hervorragend, die verschiedenen Standpunkte und Erwartungen sowohl der Unternehmer als auch der Investoren darzulegen und zu beleuchten. Während die amerikanische Biotech-Industrie lange Zeit vor der europäischen lag, holt nun jene aus "der alten Welt" rasch auf. Es ist faszinierend, wie es der Autorin gelingt, quasi eine Brücke zwischen Investorseite und Unternehmerseite zu bauen und die gemeinsamen Bedenken aufzuzeigen. Vieles des Gesagten gilt nicht nur für die pharmazeutische und chemische Industrie, sondern gleichermaßen (wenn nicht sogar in der Zukunft verstärkt) für die Kosmetikbranche. Dieses lesenswerte Buch kann daher als ein lehrreicher Ratgeber nicht nur Studenten, die eine einschlägige Industriekarriere anstreben, sondern auch Unternehmern und Investoren der Pharma-, der Riechstoff- und der Kosmetikindustrie wärmstens empfohlen werden."
EORO COSMETICS, 06/2009
See More
Interview Click here to read an interview with the author. Featured in the science section of ORF, Austrian's national public service broadcaster, in April 2009. (Interview in German)
Book Recommendation Click here to find an article about the book on the APA-FutureKnowledge website, Austrianís biggest professional communication network for science, education, technology and innovation. (Article in German)
Alexandra C. Gruber's Homepage This website gives an overview of the academic and professional career of Alexandra C. Gruber, including publications, special projects, interviews, and more
See More

Related Titles

Back to Top